The effects of other GLP-1 RAs on cardiovascular outcomes remain to be evaluated in patients with obesity or overweight, however, the results of the SELECT trial highlight the importance of treating obesity to reduce cardiovascular risk [33]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.